Dr. Harry Drabkin is professor of medicine, Gilbreth chair in clinical oncology at the Medical University of South Carolina. He received his M.D. degree from the University of Kansas, completed his internship and residency in internal medicine at the University of Cincinnati, and was a fellow in hematology-oncology at the University of Colorado. While at Colorado, Dr. Drabkin rose through the ranks to become full professor in 1998 and received the Grohne-Stapp chair in cancer research in 2006. Dr. Drabkin joined MUSC in May 2007.
Dr. Drabkin has made major contributions to our understanding of the pathogenesis of leukemia, kidney cancer and lung cancer. Among his accomplishments are the discovery of the AML1-ETO fusion transcript from the 8;21 translocation in AML, the discovery and function of the hereditary kidney cancer gene, TRC8, and the identification of the tumor suppressor gene, SEMA3F and its role and regulation in lung cancer. Clinically, Dr. Drabkin is recognized in the treatment of metastatic kidney cancer and is active in cooperative group, industry, and investigator-initiated clinical trials for this disease. He is the author of more than 160 peer-reviewed articles and book chapters.